FY2029 Earnings Forecast for ONCY Issued By HC Wainwright

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Research analysts at HC Wainwright issued their FY2029 EPS estimates for Oncolytics Biotech in a report released on Monday, February 3rd. HC Wainwright analyst P. Trucchio expects that the company will post earnings of $1.10 per share for the year. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.29) per share.

ONCY has been the topic of several other research reports. Leede Financial lowered shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday, November 13th. Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

Shares of ONCY stock opened at $0.72 on Tuesday. The firm has a market cap of $57.37 million, a price-to-earnings ratio of -2.66 and a beta of 1.24. Oncolytics Biotech has a 52 week low of $0.67 and a 52 week high of $1.53. The firm’s 50-day simple moving average is $0.85 and its two-hundred day simple moving average is $0.97.

Institutional Trading of Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Vantage Point Financial LLC purchased a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 29,744 shares of the company’s stock, valued at approximately $27,000. Hedge funds and other institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.